High expression of HOXB7 is an unfavorable prognostic factor for solid malignancies
A meta-analysis

Ting Zhou, PhD\(^a\), Zonghao Feng, MD\(^b\), Fan Yang, MD\(^a\), Weipeng Zhu, MD\(^a\), Jiashun Cao, MD\(^a\), Xianming Hou, MD\(^a\), Yue Zhao, MD\(^c\), Donghong Chen, MD\(^a\,*\)

Abstract

Background: HOXB7 is abnormally expressed in a variety of tumors, but its prognostic value remains unclear due to sample size limitation and outcome inconsistency in previous studies. This meta-analysis was performed to explore the effect of HOXB7 expression on prognoses and clinicopathological factors in range of the whole solid tumors.

Methods: PubMed, EMBASE, and Web of Science databases were searched to identify included studies. Hazard ratios (HR) with its 95% confidence interval (CI) and clinicopathological factors were extracted. Subgroup analyses were performed according to histopathological type, tumor occurrence systems, and HOXB7 detection methods.

Results: A total of 3430 solid tumors patients from 20 studies (21 cohorts) were included in the meta-analysis. The results showed that high HOXB7 expression was significantly associated with worse survival (overall survival: HR=1.98, 95%CI: 1.74–2.26, \(P<.001\) and disease-free survival: HR=1.59, 95%CI: 1.21–2.09, \(P=.001\)), more advanced tumor-node-metastasis (TNM) stage (odds ratio [OR]=2.14, 95%CI: 1.68–2.73, \(P<.001\)), positive lymph node metastasis (OR=2.16, 95%CI: 1.74–2.70, \(P<.001\)), more distant metastasis (OR=1.63, 95%CI: 1.01–2.63, \(P=.048\)), poorer differentiation (OR=1.48, 95%CI: 1.14–1.91, \(P=.003\)), and higher Ki-67 expression (OR=2.53, 95%CI: 1.68–3.84, \(P<.001\)). Subgroup analysis showed that survival of patients with HOXB7 high expression was worse in either squamous cell carcinomas or non-squamous cell carcinomas, digestive tumors or non-digestive tumors, and protein level or mRNA level.

Conclusion: High HOXB7 expression might be a valuable biomarker of poor prognosis for solid tumors. HOXB7 promotes tumor proliferation and metastasis, and is associated with poorer differentiation, more advanced stage, even the chemotherapy resistance, suggesting that HOXB7 is a potential therapeutic target for solid tumors.

Abbreviations: CI = confidence interval, DFS = disease-free survival, EMT = epithelial-mesenchymal transition, HOX = homeobox, HR = hazard ratios, OR = odds ratio, OS = overall survival, OSCC = oral squamous cell carcinoma, TAM = tamoxifen.

Keywords: biomarker, HOXB7, meta-analysis, prognosis, solid tumors

Editor: Chao Mao.
TZ and ZF contributed equally to this work.
The authors have no conflicts of interest to disclose.
Supplemental Digital Content is available for this article.
The datasets generated during and/or analyzed during the current study are not publicly available, but are available from the corresponding author on reasonable request.

\(^a\) Department of Thoracic Surgery, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, China, \(^b\) Department of Obstetrics and Gynecology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, China, \(^c\) Senior Department of Urology, the Third Medical Center of PLA General Hospital, China.

* Correspondence: Donghong Chen, Department of Thoracic Surgery, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, No. 168, Littang Rd, Changping Dist, Beijing 102218, China (e-mail: chendh_011211@btch.edu.cn).

Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and build upon the work provided it is properly cited. The work cannot be used commercially without permission from the journal.

How to cite this article: Zhou T, Feng Z, Yang F, Zhu W, Cao J, Hou X, Zhao Y, Chen D. High expression of HOXB7 is an unfavorable prognostic factor for solid malignancies: a meta-analysis. Medicine 2022;101:3(e28564).

Received: 22 January 2021 / Received in final form: 14 December 2021 / Accepted: 20 December 2021
http://dx.doi.org/10.1097/MD.0000000000028564

Keypoints

- HOXB7 high expression was correlated with worse OS and DFS in solid tumors. This OS differences existed whether in squamous or non-squamous cell carcinomas, digestive or non-digestive tumors, protein or mRNA level in subgroup analysis.
- HOXB7 high expression was correlated with poorer pathological differentiation, positive lymph-node or distant metastasis, more advanced TNM stage, and higher expression of Ki-67.

1. Introduction

As one of the leading causes of death worldwide, cancer has become the major public health problem with increasing morbidity and mortality. Statistics showed that there were 4,292,000 new cases and 2,814,000 cancer deaths in China in 2015.[1] In recent years, certain progression in early cancer screening and surgery-based comprehensive treatment have improved the 5-year overall survival (OS) of malignant tumors from 30.9% in 2003–05 to 40.5% in 2012–15.[2] However, the
curative efficacy and long-term survival of solid malignant tumor patients treated according to standard TNM staging are still largely heterogeneous. With the advent of precision treatment, it is urgent to identify novel molecular markers to monitor prognosis and guide treatment.

The homebox (HOX) genes belong to a family of transcription factors that are evolutionarily highly conserved and functionally embryonic-development promoted. The 39 HOX gene family members are arranged separately on 4 chromosomes 7p14, 17q21, 12q13, and 2q31 and correspondingly named as HOXA, HOXB, HOXC, and HOXD clusters. HOX genes are key factors in determining cell and tissue characteristics and play important roles in embryonic development. Under physical conditions, most members of this family are silenced or low-level expressed, except for structural expression in a few organs or tissues such as hematopoietic tissue, uterus in the menstrual cycle, and breast in pregnancy. Ever since the identification of the first abnormal expression of HOX gene in leukemia in 1988, the relationship between HOX genes and tumorigenesis has been successively confirmed in leukemia, kidney cancer, colorectal cancer, lung cancer, cervical cancer, breast cancer, skin cancer, ovarian cancer, and thyroid cancer. And most of the studies suggested that abnormal expression of the HOX genes contribute to tumor progression.

So far, the previous meta-analyses regarding effects of HOX gene family members on the prognoses of the patients were involved with HOXA10 and HOXA13, which showed that the expression of HOXA13 was an unfavorable prognostic factors in solid tumors and HOXA10 could serve as a tumor suppressor in prostate cancer. Moreover, there were also 2 meta-analyses on relationship between HOXB7 and cancer, one of which explored the effects of HOXB7 on tumor metastasis, and the results showed that patients with HOXB7 high expression suffered from higher rates of both lymph node metastasis and distant metastasis. Another study explored the effects of HOXB7 on the prognoses of patients with digestive system tumors. The results showed that high expression of HOXB7 was associated with poor prognosis, as well as advanced clinicopathologic characteristics such as tumor invasion, lymph node metastasis, distant metastasis, and higher TNM stage. In addition, expression of HOXB7 was also associated with lymph node metastasis and distant metastasis in variate tumors, indicating that the relationship between abnormal expression of HOX family and prognosis of cancer patients worth investigating. The 2 meta-analyses mentioned above only dealt with the relationship between HOXB7 and digestive tumors or cancer metastasis. Considering that more relevant studies with a wider perspective have come out in recent years, we conducted this meta-analysis on the relationship between HOXB7 and clinicopathological characteristics/prognosis of solid cancer patients, aiming to supplement data regarding this issue and provide some clues for clinical practice.

2. Materials and methods

The study was based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Ethics approval was not required for this research.

2.1. Literature search

A thorough literature retrieval was conducted in PubMed, EMBASE, and Web of Science database from inception to September 30, 2020 with keywords “HOXB7 OR HOX B7 OR HOXB 7 OR Homeobox B7” AND “tumor OR cancer OR carcinoma OR neoplasm”.

2.2. Study end-point

The end-points of this meta-analysis were OS and disease-free survival (DFS) of solid tumor patients.

2.3. Inclusion and exclusion criteria

Inclusion criteria: studies about the association between HOXB7 expression and prognostic parameters; the objective of the studies are solid tumor patients; the value of hazard ratios (HR) and 95% confidence interval (CI) could be extracted from the data provided; full texts are available. Exclusion criteria: duplicate publications; reviews, letters, conference reports, case reports, meta-analysis; data are incomplete or unable to be extracted.

2.4. Study screening and data extraction

According to the inclusion and exclusion criteria, 2 independent investigators separately screened and reviewed the eligible articles, and the divergent literature was consulted with a third investigator. Through a standard information collection form, the data were extracted as follows: first author, year of publication, country of origin, cancer type, pathological type, sample size, cut-off value of HOXB7 expression, patient number of HOXB7 high or low expression, HOXB7 detection method, HR, 95%CI, gender, degree of tumor differentiation, lymph node status, distant metastasis status, TNM stage, Ki67 expression level. For literature that did not directly provide HR and 95%CI, extractions were performed from Kaplan-Meier curves using Engauge Digitizer 4.1 software and the Jayne F Tierney worksheet.

2.5. Quality assessment

Quality of all included studies was systematically assessed using the Newcastle-Ottawa Scale, which consisted of 3 parts as choice of the cohort, the comparability between exposed cohort and non-exposed cohort, and the results, with a total of 8 items and 9 points. The study with a Newcastle-Ottawa Scale score ≥6 was defined as high quality.

2.6. Statistical methods

All data analyses were computed with the STATA 14 software (STATA Corporation, College Station, TX). The effect size of survival data and categorical variables was based on HR and odds ratio (OR) respectively with their 95%CI. Heterogeneity analysis was performed on all included studies using chi-square test and quantitatively assessed by $I^2$ value. If heterogeneity exists, sensitivity analysis is used to evaluate the impact on the main results. When studies were considered as mild heterogeneity ($I^2 < 50\%, \ P > .1$), the M-H fixed effect model was applied. Conversely, for studies with significant heterogeneity ($I^2 \geq 50\%, \ P \leq .1$), random effects model was applied. The effect size was measured by Z test with the level at $\alpha = 0.05$. The Begg funnel plots and Egger test were applied to assess the potential publication bias, and the test level was $\alpha = 0.05$. The effect of publication bias on the results was evaluated by the cut and fill method.
3. Results

3.1. Literature search

Initially, 700 articles were found according to the search strategy. After the screening that was carried out in strict accordance with the inclusion and exclusion criteria, 20 studies with a total of 21 cohorts (including 2 cohorts in the study of Hui et al) that published from 2010 to 2020 were finally included. A flow diagram of the literature retrieval process was shown in Figure 1. A total of 3430 solid tumor patients, including 1629 patients with high expression and 1801 patients with low expression of HOXB7. A summary of the main characteristics of the included studies was shown in Table 1.

3.2. Clinical value of HOXB7 in solid tumors

Heterogeneity test was performed for the 20 studies, $I^2 = 35.3\%$, $P = .057$, suggesting that the heterogeneity between studies was small. Sensitivity analysis was performed, and the results were consistent with the main results, indicating that the results were robust. Therefore, fixed-effects model was applied. The results showed that patients with high HOXB7 expression had worse OS and DFS than those with low HOXB7 expression, HR = 1.98, 95%CI: 1.74–2.26, $P < .001$ and HR = 1.59, 95%CI: 1.21–2.09, $P = .001$, respectively (Figs. 2 and 3). The results of subgroup analysis showed that the survival of patients with HOXB7 high expression was worse compared to those with low expression in either squamous cell carcinomas or non-squamous cell carcinomas (HR = 2.15, 95%CI: 1.76–2.63, $P < .001$ and HR = 1.92, 95%CI: 1.63–2.27, $P < .001$) (Figure S1, Supplemental Digital Content, http://links.lww.com/MD2/A834), digestive system tumors or non-digestive system tumors (HR = 2.03, 95%CI: 1.74–2.37, $P < .001$ and HR = 1.78, 95%CI: 1.41–2.25, $P < .001$) (Figure S2, Supplemental Digital Content, http://links.lww.com/MD2/A835), and protein level or mRNA level (HR = 2.03, 95%CI: 1.79–2.31, $P < .001$ and HR = 1.87, 95%CI: 1.23–2.82, $P = .003$) (Figure S3, Supplemental Digital Content, http://links.lww.com/MD2/A836) (Table 2).

In addition, correlations between HOXB7 expression and clinicopathologic factors of solid tumor patients were analyzed, including the following items: gender (male vs female), degree of tumor pathological differentiation (G3 vs G1/2) (Figure S4, Supplemental Digital Content, http://links.lww.com/MD2/A837), lymph-node status (N+ vs N–) (Figure S5, Supplemental Digital Content, http://links.lww.com/MD2/A838), distant metastasis (M1 vs M0) (Figure S6, Supplemental Digital Content, http://links.lww.com/MD2/A839), TNM staging (III–IV vs I–II) (Figure S7, Supplemental Digital Content, http://links.lww.com/MD2/A840), and Ki-67 expression (high vs low) (Figure S8, Supplemental Digital Content, http://links.lww.com/MD2/A841). The results showed that patients with high HOXB7 expression commonly had poorer tumor differentiation (OR = 1.48, 95%CI: 1.14–1.91, $P = .003$) and more advanced tumor stage (OR = 2.14, 95%CI: 1.68–2.73, $P < .001$), were prone to have lymph-node metastasis (OR = 2.16, 95%CI: 1.74–2.70, $P < .001$) and distant metastasis (OR = 1.63, 95%CI: 1.01–2.63, $P = .051$).
| Author            | Year | Country | Cancer type | Pathological type | Samples | Cut-off (high HOXB7 expression) | Detection method | OS | DFS |
|-------------------|------|---------|-------------|------------------|---------|---------------------------------|-----------------|----|-----|
| De Souza Setubal  | 2010 | Brazil  | OSCC        | Squamous         | 35      | >38.2% positive cells           | IHC             | 1.74 (0.81–3.73) | 0.08 | 2.48 (0.92–6.65) | 0.1 |
| Destro MF         | 2011 | China   | CRC         | Non-squamous     | 224     | ≥2 intensity score with ≥50% positive cells | IHC             | 2.28 (1.06–2.69) | 0.027 | NA   | NA     |
| Liu WT            | 2011 | China   | CRC         | Non-squamous     | 224     | ≥2 intensity score with ≥50% positive cells | IHC             | 2.28 (1.06–2.69) | 0.027 | NA   | NA     |
| Bitu CC           | 2012 | Brazil  | OSCC        | Squamous         | 115     | >31% positive cells             | IHC             | 2.74 (1.96–6.32) | 0.009 | 1.65 (0.78–2.41) | 0.083 |
| Nguyen Kovochich A| 2012 | America | PDAC        | Non-squamous     | 145     | Semi-quantitative histoscores >100 | IHC             | 1.50 (1.01–2.22) | 0.04  | NA   | NA     |
| Xie X             | 2013 | China   | ESCC        | Squamous         | 179     | >0.52 with 76.9% sensitivity and 42.5% specificity | qRT-PCR         | 1.86 (1.17–2.95) | 0.008 | NA   | NA     |
| Long QY           | 2014 | China   | ESCC        | Squamous         | 76      | ≥2 intensity score              | IHC             | 3.41 (1.81–6.41) | <.001 | NA   | NA     |
| Zhang R           | 2014 | China   | PDAC        | Non-squamous     | 44      | NA                              | IHC             | 2.69 (1.25–5.78) | 0.012 | NA   | NA     |
| Yuan              | 2014 | China   | LAC         | Non-squamous     | 75      | ≥3 extent score                 | IHC             | 2.15 (0.93–4.97) | <.01  | NA   | NA     |
| Li H              | 2015 | China   | ESCC        | Squamous         | 177     | ≥25% positive cells             | IHC             | 1.75 (1.04–2.93) | 0.036 | NA   | NA     |
| Tu W              | 2015 | China   | GC          | Non-squamous     | 96      | (intensity score + extent score) ≥2 | IHC             | 4.74 (1.10–20.43) | 0.001 | 3.74 (1.08–13.00) | 0.038 |
| Komatsu H         | 2016 | Japan   | HCC         | Non-squamous     | 103     | NA                              | IHC             | 2.04 (1.08–3.10) | 0.027 | NA   | NA     |
| Cai JQ            | 2016 | China   | GC          | Non-squamous     | 70      | NA                              | IHC             | 1.89 (0.75–4.8)  | 0.245 | NA   | NA     |
| Huan              | 2017 | China   | ESCC        | Non-squamous     | 77      | ≥2 intensity score with ≥0% positive cells | IHC             | 2.51 (1.52–4.13) | <.001 | NA   | NA     |
| Wang WM           | 2017 | China   | HCC         | Non-squamous     | 394     | NA                              | IHC             | 1.72 (1.33–2.23) | <.001 | 1.41 (1.10–1.81) | 0.006 |
| Zhou T            | 2017 | China   | HCC         | Non-squamous     | 143     | (intensity score + extent score) ≥2 | IHC             | 2.59 (1.59–4.2)  | <.002 | NA   | NA     |
| Fang HY           | 2019 | China   | GC          | Non-squamous     | 593     | NA                              | IHC             | 1.38 (1.14–1.68) | .002  | NA   | NA     |
| Guo Y             | 2019 | China   | HCC         | Non-squamous     | 80      | Staining score ≥2 with at least 50% of malignant cells | IHC             | 2.00 (1.10–3.40) | .014  | NA   | NA     |
| Song Z            | 2019 | China   | PCa         | Non-squamous     | 281     | NA                              | Database         | 1.58 (1.19–2.10) | .001  | NA   | NA     |
| Dai L             | 2019 | China   | ICC         | Non-squamous     | 49      | NA                              | IHC             | 2.50 (1.01–6.25) | 0.012 | NA   | NA     |
| Cai L             | 2019 | China   | HCC         | Non-squamous     | 371     | NA                              | Database         | 3.70 (2.22–6.25) | <.05  | NA   | NA     |

CI = confidence interval, CRC = colorectal cancer, DFS = disease-free survival, ESCC = esophageal squamous cell carcinoma, GC = gastric cancer, HCC = hepatocellular carcinoma, HR = hazard ratio, ICC = intrahepatic cholangiocarcinoma, IHC = immunohistochemistry, LAC = lung adenocarcinoma, NA = not available, OS = overall survival, OSCC = oral squamous cell carcinoma, PCa = prostate cancer, PDAC = pancreatic ductal adenocarcinoma, qRT-PCR = quantitative real-time polymerase chain reaction.
Figure 2. Forest plot for the relationship between HOXB7 expression and OS. OS = overall survival.

Figure 3. Forest plot for the relationship between HOXB7 expression and DFS. DFS = disease-free survival.
Table 2

Results of subgroup analysis for pooled patients with different expression of HOXB7.

| Item                          | No. of studies | No. of samples | HOXB7 Expression | OS                  | Pooled HR (95%CI) | P value | Heterogeneity |
|-------------------------------|----------------|----------------|-------------------|---------------------|--------------------|---------|---------------|
| Pathological type             |                |                |                   |                     |                    |         |               |
| Squamous                      | 6 (7 cohorts)  | 828            | High 847          | Low 341            | 2.15 (1.76–2.63)   | <.001   | 0             |
| Non-squamous                  | 14             | 2602           | High 1142         | Low 1460           | 1.92 (1.63–2.27)   | <.001   | 42.3          |
| System of occurrence          |                |                |                   |                     |                    |         |               |
| Digestive                     | 16 (17 cohorts)| 2924           | High 1357         | Low 1567           | 2.03 (1.74–2.37)   | <.001   | 42.6          |
| Non-digestive                 | 4              | 506            | High 272          | Low 234            | 1.78 (1.41–2.25)   | <.001   | 0             |
| Detection method              |                |                |                   |                     |                    |         |               |
| IHC                           | 15 (16 cohorts)| 1936           | High 1030         | Low 906            | 2.03 (1.79–2.31)   | <.001   | 0             |
| qRT-PCR                       | 2              | 249            | High 150          | Low 99             | 1.87 (1.23–2.82)   | <.001   | 0             |

CI = confidence interval, HR = hazard ratio, IHC = immunohistochemistry, OS = overall survival, qRT-PCR = quantitative real-time polymerase chain reaction.

* The fixed-effects model was applied in all subgroup analysis.

$P = .048$), and higher Ki-67 which is related to tumor proliferation (OR = 2.45, 95% CI: 1.67–3.72, $P < .001$) (Table 3).

3.3. Publication bias analysis

The Begger funnel plots and Egger test were used to quantitatively analyze the publication bias of included studies. The results showed $z = 2.26$, $Pr > |z| = 0.024$ (Fig. 4) which indicated publication bias. The influence of publication bias on the main results was analyzed by cut and fill method. The results were consistent with the main results that patient of high HOXB7 expression had worse OS (HR = 1.65, 95% CI: 1.42–1.91, $P < .001$), suggested the original results were robust.

4. Discussion

4.1. HOXB7

HOXB7, a member of the HOX gene family, is located at 17q21 and promotes ureteral development and fetal lung development. A number of studies have shown that HOXB7 is abnormally expressed in a variety of solid tumors including oral squamous cell carcinoma (OSCC), colon cancer, breast cancer, esophageal cancer, pancreatic cancer, lung cancer, gastric cancer, and liver cancer. However, the development and outcome of the disease caused by this abnormal expression are not always consistent, which is manifested in: Although most studies have supported the conclusion that abnormally high expression of HOXB7 was related to worse survival of the patients, there are still several studies with different results showing a correlation trend but without statistical significance between high expression of HOXB7 and poorer survival of salivary gland tumor patients, OSCC patients, and gastric cancer patients. However, there were some shortcomings in these 3 studies, such as the pathological types were mixed with benign and malignant tumors, which resulted in the different treatment options, most of the included patients were in stage III/IV and insufficient of sample size as well as follow-up time. Several studies showed that the correlation between high expression of HOXB7 and survival of the patients only existed in the subtypes of certain tumors. As found in studies on breast cancer, the prognosis of patients with HOXB7 high expression was only reflected in 72/286 patients that with HER-2 positive. Xie et al. also found that the prognostic advantage of low expression of HOXB7 was only reflected in the tumor of small length, early pathological T stage and pathological No. The effects of HOXB7 on tumorigenesis and cancer progression are not consistent under different time and space backgrounds. For example, Chen et al. found that overexpression of HOXB7 played a dual role in tumors in HER-

Table 3

Results of the correlations of HOXB7 expression level with clinicopathological factors.

| Item                          | No. of studies | No. of samples | HOXB7 Expression | OR (95%CI) | P value | Heterogeneity |
|-------------------------------|----------------|----------------|------------------|------------|---------|---------------|
| Gender (male vs female)       | Male           | 16 (17 cohorts)| 2072             |            |         |
|                               | Female         |                |                  | 833        | 629     | 1.18 (0.97–1.44) | .108     | 0             |
|                               |                |                |                   | 329        | 281     |               |
| Differentiation (G3 vs G1/2)  | G3             | 12 (13 cohorts)| 1297             |            |         |
|                               | G1/2           |                |                  | 271        | 168     | 1.48 (1.14–1.91) | .003     | 13            |
|                               |                |                |                   | 461        | 397     |               |
|                               |                |                |                   | 464        | 246     | 2.16 (1.73–2.69) | <.001    | 0             |
|                               |                |                |                   | 379        | 40      |               |
| Lymph-node status (N+ vs N-)  | N+             | 12 (13 cohorts)| 1492             |            |         |
|                               | N-             |                |                  | 62         | 34      | 1.63 (1.01–2.63) | .048     | 0             |
|                               |                |                |                   | 314        | 239     |               |
| Distant metastasis (M1 vs M0) | M1             | 6              | 649              |            |         |
|                               | M0             |                |                  | 62         | 34      | 1.63 (1.01–2.63) | .048     | 0             |
|                               |                |                |                   | 314        | 239     |               |
| Stage (III/IV vs I/II)        | III/IV         | 11 (12 cohorts)| 1279             |            |         |
|                               | I/II           |                |                  | 374        | 164     | 2.14 (1.68–2.73) | <.001    | 27.9          |
|                               |                |                |                   | 394        | 347     |               |
| Ki-67 expression (high vs low)| High           | 3              | 374              |            |         |
|                               | Low            |                |                  | 121        | 71      | 2.45 (1.67–3.72) | 0        | 0.1           |
|                               |                |                |                   | 74         | 108     |               |

CI = confidence interval, OR = odds ratio.

* The fixed-effects model was applied in all subgroup analysis.
2/neu-induced breast cancer mouse models, which inhibited tumorigenesis initially, but promoted subsequent progression and metastasis of the tumor. On the other hand, the promotion function of HOXB7 in the double-strand break repair process suggested that HOXB7 promotes normal cell repair before tumorigenesis, however, once tumor occurs, it would in turn promote the damage repair of tumor cell, including the damage caused by chemotherapeutic drugs such as cisplatin, of which the main mechanism is DNA damage. Therefore, HOXB7 has a role in tumor progression or drug resistance. For the function itself, HOXB7 promotes tissue differentiation as an embryo-related gene, but it also promotes de-differentiation of mature tissues and acquisition of cell stemness. Therefore, a meta-analysis would facilitate a more comprehensive understanding of the prognostic significance of HOXB7 in solid tumors.

4.2. HOXB7 is a poor prognostic factor for solid malignant tumors

The solid tumor types in this meta-analysis included OSCC, esophageal squamous cell carcinoma, gastric cancer, colorectal cancer, liver cancer, pancreatic cancer, lung adenocarcinoma, and salivary gland cancer. It was found that the expression of HOXB7 was higher in cancer tissues as compared with that in normal tissues, either at mRNA or protein levels. The pooled analysis showed that the OS and DFS of HOXB7 high expressed patients were worse than those with low expression of HOXB7. Further subgroup analysis showed that the survival disadvantage of HOXB7 high expression was commonly found in squamous cell carcinomas and non-squamous cell carcinomas, digestive system tumors and non-digestive system tumors, protein level and mRNA level. Therefore, the results of this study suggested that HOXB7 high expression was one of the unfavorable prognostic factors for solid malignancies. HOXB7 affects the biological behavior of solid malignant tumors and the prognosis of patients in many aspects as follows.

4.2.1. Clinicopathological aspects. The results showed that patients with HOXB7 high expression often had more advanced TNM stages (P < .001), higher lymph-node metastasis rate (P < .001) and distant metastasis rate (P = .048), poorer pathological differentiation (P = .003), and higher Ki-67 expression (P < .001).

4.2.2. Cell biological properties. It has been found in previous studies that HOXB7 high expression promoted malignant biological behavior such as acceleration of cell proliferation, inhibition of apoptosis, acquisition of cell stemness, and enhancement of motility and angiogenesis.[2,22,23]

4.2.2.1. HOXB7 effects PI3K/AKT and MAPK pathways. He et al.[24] found in gastric cancer that HOXB7 promoted cell proliferation, inhibited apoptosis, and induced epithelial-mesenchymal transition (EMT) and metastasis by activating PI3K/AKT and MAPK pathways. Further, Liao et al.[25] demonstrated in colorectal cancer that by activating these pathways, HOXB7 modulated checkpoint proteins (up-regulated Cyclin D1 and down-regulated P27Kip1), which accelerated G1-S cell cycle transition and cell proliferation. Huan et al.[26] found that HOXB7 promoted the stemness acquisition of hepatoma cells by regulating PI3K/AKT/c-Myc axis, and promoted EMT by regulating PI3K/AKT/Slug axis to accelerate the malignant progression of hepatocellular carcinoma.

4.2.2.2. HOXB7 promotes the expression of basic fibroblast growth factor in the downstream. In melanoma and ovarian cancer, HOXB7 was identified to activate basic fibroblast growth factor and promote cell proliferation. Further, in hepatocellular carcinoma and breast cancer, the activation of HOXB7 on basic fibroblast growth factor was found to be direct, and the MAPK pathway was thereby activated to promote proliferation and EMT, which further induced cancer cells toward a more aggressive phenotype.[27–30]

4.2.2.3. HOXB7 regulates the angiogenesis-related factors. Previous study has found that HOXB7 was involved in angiogenesis by up-regulating vascular endothelial growth factor A, fibroblast growth factor-2, matrix metalloproteinase-2, WNT5a and platelet derived growth factor A, and down-regulating thrombospondin-2[31] in myeloma cancer. Meanwhile, in HOXB7-transfected breast cancer cells, except for VEGF, the expression of interleukin-8 and angiopoietin-2 was also upregulated.[31,32] In cervical cancer, VEGF was verified as a downstream transcription regulator by HOXB7, therefore, the miR-196b/HOXB7/VEGF axis played a critical role in the development and progression of cervical cancer.[33] Additionally, high expression of HOXB7 was also detected in the hemangio-metastoma model.[34]

4.3. Treatment resistance

Related studies have found that treatment resistance caused by HOXB7 high expression is another important reason for poor prognosis of the patients. Jin et al.[33] found that HOXB7 is an ERα response gene. In ERα breast cancer patients, after the treatment of tamoxifen (TAM), HOXB7 expression increased and binded with EGFR promoter, which resulted in the enhancement of the transcriptional activity and expression of EGFR, and ultimately lead to TAM resistance and poor prognosis. Interestingly, this TAM resistance would be reversed by HOXB7 siRNA. Therefore, HOXB7 expression in ERα breast cancer might be an indicator for anti-EGFR therapy. In addition,
Rubin et al.\(^{[36]}\) found that the human mammary epithelial cell line MCF10A transformed by exogenous HOXB7 was more resistant to ionizing radiation. They found 4 proteins, Ku70, Ku80, DNA-PKcs, and PARP, which could bind to HOXB7 directly by GST pull-down/affinity chromatography and immunoprecipitation. The 4 proteins were considered to be DNA repair related proteins, suggesting that HOXB7 is involved in the repair of non-homologous end joining of double-strand break, which was further confirmed in colon cancer.\(^{[35]}\) In addition, in the studies of lung cancer, esophageal cancer and cervical cancer, it has been confirmed that the high expression of the above 4 non-homologous end joining-related molecules was associated with resistance to chemoradiotherapy.\(^{[37-41]}\) Therefore, the expression of HOXB7 might be an indicator for the sensitivity of radiotherapy and/or chemotherapy.

5. Conclusion
High expression of HOXB7 promoted tumor proliferation and metastasis, and were associated with poor differentiation, more advanced stage, as well as chemotherapy resistance. Therefore, HOXB7 might be a valuable prognostic biomarker for human solid tumors. When HOXB7 expression was suppressed, its adverse effects could be alleviated, suggesting that HOXB7 is a potential therapeutic target in solid malignancies.

Author contributions
Methodology: Ting Zhou, Zonghao Feng, Fan Yang, Weipeng Zhu, Jiashun Cao, Xianming Hou, Yue Zhao.
Software: Ting Zhou, Zonghao Feng, Fan Yang, Weipeng Zhu, Jiashun Cao, Xianming Hou.
Supervision: Donghong Chen.
Writing – original draft: Ting Zhou.
Writing – review & editing: Zonghao Feng.

References
[1] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016;66:115–32.
[2] Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health 2018;6:e335–67.
[3] Bondos SE, Tan XX, Matthews KS. Physical and genetic interactions link hox function with diverse transcription factors and cell signaling proteins. Mol Cell Proteomics 2006;5:824–34.
[4] Garin E, Lemieux M, Coulombe Y, Robinson GW, Jeannotte L. Stromal HoxA5 function controls the growth and differentiation of mammary alveolar epithelium. Dev Dyn 2006;235:1858–71.
[5] Taghon T, Thys K, De Smedt M, et al. Homeobox gene expression profile in human hematopoietic multipotent stem cells and T-cell progenitors: implications for human T-cell development. Leukemia 2003;17:1157–63.
[6] Lu Z, Hardt J, Kim JJ. Global analysis of genes regulated by HOXA10 in decidualization reveals a role in cell proliferation. Mol Hum Reprod 2008;14:357–66.
[7] Kongswan K, Webb E, Houssaux P, Adams JM. Expression of multiple homeobox genes within diverse mammalian haematopoietic lineages. EMBO J 1988;7:2131–8.
[8] Athate-Shen C. Deregulated homeobox gene expression in cancer: cause or consequence? Nat Rev Cancer 2002;2:777–85.
[9] Hatanaka Y, de Velasco MA, Oki T, et al. HOXA10 expression profiling in prostate cancer. Prostate 2019;79:534–63.
[10] Deng Y, He R, Zhang R, et al. The expression of HOXA13 in lung adenocarcinoma and its clinical significance: a study based on The Cancer Genome Atlas, Oncomine and reverse transcription-quantitative polymerase chain reaction. Oncol Lett 2018;15:8556–72.

[11] Liu FT, Ou XY, Zhang GP, Qiu C, Luo HL, Zhu PQ, HOXB7 as a promising molecular marker for metastasis in cancers: a meta-analysis. Onco Targets Ther 2016;9:2693–9.
[12] Liu FT, Chen HM, Xiong Y, Zhu ZM. Deregulated HOXB7 expression predicts poor prognosis of patients with malignancies of digestive system. Mediterr J Hematol Infect Dis 2019;11:e20230.
[13] Yu OH, Murawski JJ, Myburgh DB, Gupta IR. Overexpression of RET leads to vesicoureteric reflux in mice. Am J Physiol Renal Physiol 2004;287:F1123–30.
[14] Chi X, Hadjantonakis AK, Wu Z, Hynck D, Costantini F. A transgenic mouse that reveals cell shape and arrangement during ureretic bud branching. Genesis 2009;47:61–6.
[15] Grier DG, Thompson A, Lappin TR, Halliday HL. Quantification of hox and surfactant protein-B transcription during murine lung development. Neonatology 2009;96:50–60.
[16] Errico MC, Jin K, Sukumar S, Care A. The widening sphere of influence of HOXB7 in solid tumors. Cancer Res 2016;76:2857–62.
[17] Fonseca FP, Bingle L, Santos-Silva AR, et al. Immunexpression of hoxb7 and hoxb9 in salivary gland tumours. J Oral Pathol Med 2016;45:672–81.
[18] Rivera C, Gonzalez-Arriagada WA, Loyola-Brambilla M, de Almeida OP, Coletta RD, Venegas B. Clinicopathological and immuno-histochemical evaluation of oral and oropharyngeal squamous cell carcinoma in Chilean population. Int J Clin Exp Pathol 2014;7:9568–77.
[19] Cai JQ, Xu WX, Mou YP, Chen K, Pan Y, Wu D. Upregulation of HOXB7 promotes the tumorigenesis and progression of gastric cancer and correlates with clinical characteristics. Tumour Biol 2016;37:1641–50.
[20] Chen H, Lee JS, Liang X, et al. Hoxb7 inhibits transgenic HER-2/neu-induced mouse mammary tumor onset but promotes progression and lung metastasis. Cancer Res 2008;68:3637–44.
[21] Xie X, Zhang SS, Wen J, et al. Prognostic value of HOXB7 mRNA expression in human oesophageal squamous cell cancer. Biomarkers 2013;18:297–303.
[22] Samuel S, Naora H. Homeobox gene expression in cancer: insights from developmental regulation and deregulation. Eur J Cancer 2003;41:2428–37.
[23] Shah N, Sukumar S. The Hox genes and their roles in oncogenesis. Nat Rev Cancer 2010;10:361–71.
[24] He X, Liu Z, Xia Y, et al. HOXB7 overexpression promotes cell proliferation and correlates with poor prognosis in gastric cancer patients by inducing expression of both AKT and MARKs. Oncotarget 2017;8:1247–61.
[25] Liao WT, Jiang D, Yuan J, et al. HOXB7 as a prognostic factor and mediator of colorectal cancer progression. Clin Cancer Res 2011;17:3569–78.
[26] Huan HB, Yang DP, Wen XD, et al. HOXB7 accelerates the malignant progression of hepatocellular carcinoma by promoting stemness and epithelial-mesenchymal transition. J Exp Clin Cancer Res 2017;36:86.
[27] Care A, Silvana A, Meccia E, et al. HOXB7 constitutively activates basic fibroblast growth factor in melanomas. Mol Cell Biol 1996;16:4982–51.
[28] Naora H, Yang YQ, Montz FJ, Seidman JD, Roden RB. A serologically identified tumor antigen encoded by a homeobox gene promotes growth of ovarian epithelial cells. Proc Natl Acad Sci U S A 2001;98:4060–5.
[29] Wang WM, Xu Y, Wang YH, et al. HOXB7 promotes tumor progression via bFGF-induced activation of MAPK/ERK pathway and indicated poor prognosis in hepatocellular carcinoma. Oncotarget 2017;8:47121–35.
[30] Wu X, Chen H, Parker B, et al. HOXB7, a homeodomain protein, is overexpressed in breast cancer and confers epithelial-mesenchymal transition. Cancer Res 2006;66:9527–34.
[31] Storti P, Donofrio G, Colla S, et al. HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients. Leukemia 2011;25:327–37.
[32] Care A, Felicetti F, Meccia E, et al. HOXB7: a key factor for tumor-associated angiogenic switch. Cancer Res 2001;61:6332–9.
[33] How C, Hui AB, Ajalej NM, et al. MicroRNA-196b regulates the homeobox B7-vascular endothelial growth factor axis in cervical cancer. PLoS One 2013;8:e67846.
[34] Kodama A, Sakai H, Matsura S, et al. Establishment of canine hemangiosarcoma xenograft models expressing endothelial growth factors, their receptors, and angiogenesis-associated homeobox genes. BMC Cancer 2009;9:363.
[35] Jin K, Kong X, Shah T, et al. The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. Proc Natl Acad Sci U S A 2012;109:2736–41.
[36] Rubin E, Wu X, Zhu T, et al. A role for the HOXB7 homeodomain protein in DNA repair. Cancer Res 2007;67:1527–35.
[37] Soret C, Martin E, Duluc I, et al. Distinct mechanisms for opposite functions of homeoproteins Cdx2 and HoxB7 in double-strand break DNA repair in colon cancer cells. Cancer Lett 2016;374:208–15.
[38] Omori S, Takiguchi Y, Suda A, et al. Suppression of a DNA double-strand break repair gene, Ku70, increases radio- and chemosensitivity in a human lung carcinoma cell line. DNA repair 2002;1:299–310.
[39] Singh A, Singh N, Behera D, Sharma S. Role of polymorphic XRCC6 (Ku70)/XRCC7 (DNA-PKcs) genes towards susceptibility and prognosis of lung cancer patients undergoing platinum based doublet chemotherapy. Mol Biol Rep 2018;45:253–61.
[40] Zhao HJ, Hosoi Y, Miyachi H, et al. DNA-dependent protein kinase activity correlates with Ku70 expression and radiation sensitivity in esophageal cancer cell lines. Clin Cancer Res 2000;6:1073–8.
[41] Zhuang L, Liu F, Peng P, et al. Effect of Ku80 on the radiosensitization of cisplatin in the cervical carcinoma cell line HeLa. Oncol Lett 2018;15:147–54.